![]() |
|
|
Vol. 14, Issue 8, 3208-3215, August 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




** 

* Department of Surgery, Stanford University School of Medicine, Stanford,
California 94305;
Department of Biochemistry, Stanford University School of Medicine, Stanford,
California 94305;
# Department of Genetics, Stanford University School of Medicine, Stanford,
California 94305;
** Department of Howard Hughes Medical Institute, Stanford University School of
Medicine, Stanford, California 94305;
Department of Pathology, The University of Hong Kong, Hong Kong, China;
¶ Department of Surgery, The University of Hong Kong, Hong Kong, China; and
|| Department of Surgery, Perking University School of Oncology, Beijing Cancer
Hospital, Beijing, China
Submitted December 18, 2002;
Revised February 24, 2003;
Accepted March 17, 2003
Monitoring Editor: Keith Yamamoto
| ABSTRACT |
|---|
|
|
|---|
30,300 genes. Gastric cancers were distinguished from
nonneoplastic gastric tissues by characteristic differences in their gene
expression patterns. We found a diversity of gene expression patterns in
gastric cancer, reflecting variation in intrinsic properties of tumor and
normal cells and variation in the cellular composition of these complex
tissues. We identified several genes whose expression levels were
significantly correlated with patient survival. The variations in gene
expression patterns among cancers in different patients suggest differences in
pathogenetic pathways and potential therapeutic strategies. | INTRODUCTION |
|---|
|
|
|---|
The prognosis of gastric cancer depends heavily on tumor stage at
diagnosis. Surgical resection, still the mainstay of treatment, is very
effective in early stage cancer. Most patients present in advanced stages,
however, when the prognosis is extremely poor. Recent studies have shown that
comprehensive analysis of gene expression patterns can identify new molecular
criteria for classification and prognostication of diverse cancers. The
molecular portraits provided by the tumors' gene expression patterns provide a
basis for recognizing new subtypes of cancer that, although morphologically
indistinguishable, differ in clinical behavior, molecular pathways of tumor
development, and underlying genetic predisposition
(Alizadeh et al.,
2000
; Perou et al.,
2000
; Dhanasekaran et
al., 2001
; Garber et
al., 2001
; Hedenfalk
et al., 2001
;
Rosenwald et al.,
2001
; Sorlie et al.,
2001
; Pomeroy et al.,
2002
; Rosenwald et
al., 2002
; van `t Veer
et al., 2002
).
Previous studies have reported expression profiles in small numbers of
gastric cancer samples, identifying a few hundred genes that distinguish tumor
from normal tissue (El-Rifai et
al., 2001
; Hippo et
al., 2002
). However, these studies were too small to
distinguish subgroups or identify any genes whose expression may be correlated
with clinical outcomes. Here we describe a systematic study of gene expression
patterns in gastric adenocarcinomas and nonneoplastic gastric mucosa. The
results define potential molecular criteria for disease classification, early
detection, and prognostication as well as providing new insights into the
pathogenesis and progression of gastric cancers.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Tumors were classified using the Lauren's classification into intestinal,
diffuse, mixed and indeterminate types
(Lauren, 1965
). The presence
of H. pylori in the gastrectomy specimens was determined by
histological examination, supplemented by modified Giemsa staining. The
presence of EBV in cancer cells was assayed by in situ hybridization for EBER
as described previously (Yuen et
al., 1994
). The tumor stage was defined by the General Rules
for Gastric Cancer Study of the Japanese Research Society for Gastric Cancer
(Nishi et al.,
1995
).
Microarray Procedure and Data Analysis
We used cDNAs microarray containing 44,500 cDNA clones, representing
30,300 unique genes. The methods for microarray production and
hybridization, and data analysis, including hierarchical clustering, closely
followed previously described procedures
(Alizadeh et al.,
2000
; Perou et al.,
2000
). In brief, 2 µg of sample mRNA and 2 µg of reference
mRNA were used as template for synthesis of cDNA, labeled with Cy5-dUTP and
Cy3-dUTP (Amersham, Piscataway, NJ), respectively, using reverse transcriptase
(Invitrogen) for 2 h at 42°C. The two labeled cDNA samples were separated
from unincorporated nucleotides by filtration, mixed, and hybridized to
microarray at 65°C overnight. After hybridization, each microarray was
washed with 2x SSC, 0.03% SDS for 5 min at 65°C and then with
1x SSC for 5 min and 0.1x SSC for 5 min, both at room temperature.
The array was then scanned with a GenePix 4000B microarray scanner (Axon
Instruments, Union City, CA). Primary data collection and analysis were
carried out using GenePix Pro3.0 (Axon Instruments). Areas of the array with
obvious blemishes were manually flagged and excluded from subsequent analysis.
The raw data were deposited into Stanford Microarray Database
(Sherlock et al.,
2001
) at:
http://genome-www4.stanford.edu/MicroArray/SMD/index.html.
Statistical Analysis
We selected nonflagged array elements for which the fluorescent intensity
in either channel was greater than 3 times the local background. Genes for
which fewer than 80% of measurements met this standard, across all the samples
in this study, were excluded from the analysis. We further selected genes
whose expression level differed by at least 2.5-fold, in at least three
samples, from their mean expression level across all samples for hierarchial
clustering. Before the statistical analysis, the missing values in the dataset
were estimated by a KNN impute algorithm using 12 neighbors
(Troyanskaya et al.,
2001
). A nonparametric t test with p value cutoff of
0.001 or 0.002 based on 10,000 random column permutations was used to identify
genes differentially expressed in gastric cancer and nonneoplastic gastric
tissue samples (Troyanskaya et
al., 2002
). The false discovery rate (FDR) was estimated
based on the number of genes that passed the p value cutoff of 0.001 or 0.002
in five datasets with randomized columns. Cox regression survival analysis was
performed to identify genes whose expression levels correlated with patient
survival, using the Cox regression function in the statistical package R
(http://lib.stat.cmu.edu/R/CRAN).
The p value reflecting the correlation of each gene's expression pattern with
patient survival was calculated individually using the Cox function in SPSS,
without adjustment for multiple testing, therefore, the p values presented in
the article might overestimate statistical significance because of multiple
hypothesis testing.
| RESULTS AND DISCUSSION |
|---|
|
|
|---|
30,300
different genes, we profiled mRNA populations in 90 primary gastric
adenocarcinomas, lymph node metastases from 14 of the same 90 tumors, and 22
samples of nonneoplastic gastric mucosa adjacent from resected tumors,
representing both antrum (12 samples) and body (10 samples). Among the 12
antral tissues, 7 showed intestinal metaplasia. From the roughly 30,000 genes
whose expression was measured in these samples, we identified a set of
5200 genes whose transcripts varied by at least 2.5-fold from their mean
abundance in the sample set, in at least 3 samples
(Figure 1). We used a
hierarchical clustering method to group these genes on the basis of similarity
in expression across the samples and to group samples based on similarity in
their gene expression patterns.
|
Heterogeneity of the Gene Expression Patterns among Gastric Cancer
Tissues
Simple hierarchical clustering analysis readily segregated nontumor samples
from all the tumors and revealed complex variations in gene expression
patterns among the gastric cancers. Eleven of the 14 lymph node metastases
were clustered with primary tumor from which they arose, implying that the
gene expression patterns in the metastatic tumor masses were more similar to
the patterns in the corresponding primary tumors than to any of the other
metastatic or primary tumors. The three exceptions were attributable to
differences between the primary and metastatic tumors in the admixture of
nontumor cells; when hierarchical clustering of the tumors was carried out
based on expression of set of genes that excluded genes characteristically
expressed in lymphocytes and stromal cells, all 14 pairs of primary and
metastatic tumors from the same patient clustered together as nearest
neighbors (see Web supplement). This result implies that each gastric cancer
has a unique characteristic gene expression pattern and that the distinctive
features of these molecular portraits are maintained even when tumors
metastasize to the lymph node. We can use these 14 paired samples to identify
a set of "intrinsic genes," whose expression levels vary widely
among tumors from different patients, but are closely matched in primary and
metastatic tumors from the same patient. These genes are likely to be
especially useful for recognition of molecular subtypes of gastric cancer
(Perou et al., 2000
;
see Web supplement).
Genes with consistent differences in expression between the gastric cancer
and the nonneoplastic gastric tissues are of particular interest. Using a
nonparametric t test, we identified 2656 genes whose expression
levels were significantly different between tumor and normal tissues, with
p
0.001 and a false discovery rate of 0.13% (see Web
supplement).
A cluster of
2000 genes was expressed at higher levels in most of
gastric cancers compared with nontumor tissues
(Figure 1). Among these 2000
genes were a group of genes associated with cell cycle progression, the
"proliferation cluster" (Iyer
et al., 1999
;
Whitfield et al.,
2002
), whose transcripts were generally much more abundant in the
tumors than in nonneoplastic tissues, though their levels varied considerably
among the tumor samples (Figure
2c).
|
Several clusters of genes that appear to reflect primary events important
for gastric carcinogenesis, such as chromosomal amplifications or alterations
in transcriptional regulators or signal transduction pathways, were
specifically associated with subsets of these cancers. For example, cyclinE1,
POP4, RMP, UQCRFS1, and DKFZP762D096 were coexpressed at greatly elevated
levels in
10% of gastric tumors
(Figure 2a). All these genes
are located on chromosome 19q12-13, suggesting amplification of a locus
containing CyclinE1 in this group of tumors. Similarly, in
10% of tumors,
a cluster of genes including ErbB2 and two neighboring genes on chromosome
17q12-21 (Grb7 and MLN64), showed markedly elevated expression, strongly
suggesting amplification of the ErbB2 locus in these tumors
(Figure 2b).
Another cluster of genes jointly expressed at elevated levels in some
gastric cancers included AXIN2 and beta-catenin
(Figure 2d). AXIN2 is induced
by beta-catenin/TCF as part of an auto-regulatory pathway in Wnt signaling.
Colorectal and liver tumors with activation of the Wnt signaling pathway have
been shown consistently to express a high level of AXIN2
(Lustig et al.,
2002
). Activation of this pathway by mutations in APC or
beta-catenin leads to increased levels of beta-catenin and its nuclear
localization (Korinek et al.,
1997
). Indeed, immunohistochemical staining revealed nuclear
beta-catenin in many of the gastric tumors that express high levels of AXIN2
(see Web supplement). Abnormal activation of the Wnt pathway may therefore
play a role in the pathogenesis of this distinct subgroup of gastric tumors.
This gene cluster also included EphB2, a member of the Eph receptor tyrosine
kinases. Ephrin signaling has been shown to be important in embryonic
development, including axon guidance and angiogenesis
(Kullander and Klein, 2002
).
This pathway has also been implicated in promoting tumorgenesis
(Dodelet and Pasquale, 2000
). A
recent study showed that the activation of beta-catenin led to high expression
of EphB receptors and that expression of EphB is crucial for the correct
positioning of epithelial cells in gut
(Batlle et al., 2002
).
It is therefore interesting to note that EphB2 coclustered with beta-catenin
and AXIN2 because of its patterns of expression in these gastric cancer
tissues. The relationship of expression of EphB and Wnt signaling pathways in
gastric cancer development deserves further investigation.
Clusters of genes that were generally more highly expressed in normal
gastric mucosa than in gastric cancers are also of considerable interest
(Figure 2, e and f). Among
them, many are known to have role in the digestive function of the stomach or
the integrity of the mucosa, such as pepsinogen C, carbonic anhydrase II,
specific subtypes of gastric mucins (MUC5AC and MUC6) and somatostatin. Some
putative tumor suppressor genes or genes with known growth inhibitory effects
in the gastrointestinal tract can also be found in this cluster. These include
TFF1mice lacking TFF1 develop gastric adenomas and intramucosal
carcinomas (Lefebvre et al.,
1996
)and CDKN1C, the gene encoding the p57KIP2
cyclin-dependent kinase inhibitor, whose promoter has been found to be
methylated, accompanied by transcriptional silencing, in some gastric cancer
cell lines (Shin et al.,
2000
).
Gastric cancer is a histologically complex tissue. The reciprocal interactions between tumor cells and stromal cells play important roles in tumor biology. A cluster of genes, including many that encode extracellular matrix components, appears to reflect variation in the proportion of stromal cells in the tumor. The genes in this cluster tend to be significantly more highly expressed in tumors of the diffuse histological type than in tumors of the intestinal type (see Web supplement), consistent with greater propensity of this group of tumors for invasive growth, often provoking a dense fibrous reaction. The expression patterns of two clusters of genes, which we term the "leukocyte" and "interferon" clusters, respectively, appear to reflect the density, composition, and physiology of infiltrating leukocytes. The genes in these two clusters were generally significantly more highly expressed in the EBV-associated tumors (see Web supplement), consistent with previous reports that these EBV-associated gastric cancers are often, though not invariably, accompanied by intense lymphoid infiltrate. A cluster of genes that included immunoglobulin genes was expressed at high levels in gastric mucosa and in some tumors, and their expression correlated well with the number of plasma cells as determined by histological examination (see Web supplement). Similarly, a cluster enriched in genes characteristically expressed by smooth muscle appears to reflect adventitious smooth muscle cells in the samples (see Web supplement).
A Gene Expression Pattern Associated with Intestinal Metaplasia
Defines a Distinct Subset of Gastric Cancers
Gastric cancers frequently arise in a background of chronic gastritis with
intestinal metaplasia. As a step toward understanding this relationship, we
explored the variations in gene expression patterns in different anatomical
regions of the normal stomach, in metaplastic gastric mucosa, and in samples
of normal mucosa from small intestine and colon (displayed to the right of the
main cluster; Figure 3). Based
on their global gene expression patterns, the samples of nonneoplastic gastric
mucosa were segregated into three branches, one corresponding to the gastric
body and the other two corresponding to antral mucosa with and without
intestinal metaplasia, respectively.
|
Three prominent gene clusters distinguished these three different types of gastric mucosa. A group of genes were expressed selectively in gastric body, but not in antrum, small intestine or colon, nor, to any significant degree, in gastric tumors (Figure 3a). This group included genes involved in transport (KCNJ16) and proteolysis (PSMB9), presumably reflecting functional specialization of the mucosa of the gastric body. A second cluster of genes, expressed at high level in metaplastic mucosa, but very little in nonmetaplastic mucosa and most gastric tumors (Figure 3b), included genes with roles in lipid (MTP, FABP1, APOA1), amino acid (GGT1), or glucose (ALDOB) transport or metabolism. Most of these genes are also highly expressed in small intestine and to a lesser extent in the colon. The third cluster of genes, also highly expressed in metaplastic antral mucosa compared with nonmetaplastic gastric mucosa, appears to be related to the control of intestinal differentiation (Figure 3c). Genes in this cluster include transcription factors that are involved in inducing and maintaining differentiation of the small and large intestine (CDX1, CDX2, and HNF4A) as well as integral membrane proteins and adhesion molecules that are characteristic of intestinal epithelium (CLDN3, CLDN4, CDH17, and VIL1). The genes in this cluster are expressed in small intestine and colon mucosa, supporting their association with intestinal differentiation. Surprisingly, this group of genes was also expressed at high levels in many gastric cancers. On the basis of expression of 41 genes in the cluster, the 90 gastric cancer samples can be segregated into two groups, which for the purpose of this discussion, we labeled "intestinal-like" and "gastric-like" (Figure 3d). We hypothesized that tumors showing intestinal-like gene expression patterns were derived from gastric mucosa cells that have undergone intestinal metaplasia.
Gastric cancer is traditionally classified into two subtypes based on their
histological architecture (Lauren,
1965
). The "intestinal type," characterized by
cohesive growth of cells in quasi-glandular structures, has been presumed to
arise secondarily from intestinal metaplasia, whereas the "diffuse
type," in which tumor cells were dispersed and generally not organized
into glandular structures, has been thought to arise directly from
nonmetaplastic foveolar or mucous neck cells
(Grabiec and Owen, 1985
). We
therefore explored the relationship between expression of this intestinal
differentiation gene cluster and the two histologically defined cancer
subtypes. To our surprise, the intestinal-like gene expression pattern was
seen with equal frequency in the histologically defined intestinal and diffuse
groups (Figure 3d and Web
supplement). In contrast, there was a strong association between the
intestinal-like gene expression pattern and the presence of intestinal
metaplasia at the tumor edge (p < 0.001;
Figure 3d and Web supplement).
Our data therefore suggest the possibility that the intestinal-like gastric
cancers, as defined based on their gene expression patterns, may arise from
gastric mucosal cells that have previously undergone intestinal metaplasia and
thus retain the molecular signature of the intestinal enterocyte, whereas the
gastric-like cancers may arise by alternative pathway that does not involve
intestinal metaplasia as an intermediate step. It will be important in
following up these results to focus for the attention on the progression of
events involved in metasplasia and gastric cancer development.
Our identification of a transcriptional program related to intestinal differentiation in gastric cancer provides one potential basis for extending classification of gastric cancer beyond morphological distinctions. Antibodies against proteins encoded by genes in the "intestinal differentiation" cluster may provide a convenient adjunct to conventional histopathology in classifying gastric cancers. Because the distinct molecular phenotypes of the intestinal-like and gastric-like gastric cancers are likely to have counterparts in the physiology and behavior of the tumors, recognition of these differences may be of significant value in evaluating clinical behavior and treatment trials.
Differential Expression of the Molecular Targets of Potential
Therapeutic Agents
Specific features of the gene expression programs that distinguish gastric
cancers may not only provide clues to differences in their regulation but may
provide critical information for individualized therapy using molecularly
targeted treatment modalities. For example, TACSTD1, which encodes a
homophilic calcium-independent cell adhesion molecule, is among the genes
characteristically expressed in the intestinal-like subset of gastric cancers.
An mAb (CO171A) against this protein has shown considerable promise in
treatment of colorectal cancer in phase II/III randomized clinical trials
(Riethmuller et al.,
1998
). The differential expression of this gene among gastric
cancers suggests its potential selective application in treatment of patients
with intestinal-like gastric cancer. Similarly, the elevated expression of the
EGF receptor in
15% of gastric cancers suggests that these patients may
benefit from compounds (both small molecular inhibitors and monoclonal
antibodies) that target this protein, which have shown promise in clinical
trials against a variety of cancers, and the highly elevated expression of
ErbB2 in a small but significant fraction of gastric cancers raises the
possibility that this group of patients may benefit from treatment with
Herceptin.
Gene Expression Patterns and Infectious Etiologies
Despite the strong association between H. pylori infection and
gastric cancer, we were unable to identify genes whose expression levels were
significantly associated with H. pylori infection. Although the
intestinal-like gene expression pattern was somewhat more common than the
gastric-like pattern in cancers associated with H. pylori infection,
the difference was not statistically significant (see Web supplement). The
critical role that H. pylori infection can play in the pathogenesis
of gastric cancer may precede the development of overt cancers by many years.
Therefore, histological evidence of contemporaneous H. pylori
infection in the surgical samples may not reflect the role this infection
played in the development of a tumor. It will be of great interest in future
studies to compare gene expression patterns in gastric cancer with a more
comprehensive assessment of the patient's past history of H. pylori
infection.
The expression levels of 326 genes showed a significant association with
EBV infection (p < = 0.002, and FDR = 5%; see Web supplement). Some of
these genes appeared to be related to the lymphoid infiltrate often observed
in EBV+ gastric cancers. Among the 135 genes whose expression tended to be
significantly higher in the EBV+ cancers was p53, consistent with previous
reports of elevated p53 expression by a nonmutational mechanism in these
tumors (Leung et al.,
1998
; Wu et al.,
2000
). Interestingly, we found that most (11/12) EBV-associated
gastric cancers had the gastric-like gene expression phenotype (p = 0.007)
(Figure 3d and Web supplement),
although most of these tumors would be classified as intestinal by
histopathology. The role of EBV in the pathogenesis of this distinct type of
gastric cancer will be an interesting question for future investigation.
Expression Patterns Significantly Correlated with Patient
Survival
We identified several genes whose expression levels in the gastric cancer
samples were significantly associated with patient survival (see Web
supplement). These genes define molecular markers that may be immediately
useful for prognosis and treatment stratification. Clearly, it will be
important to corroborate the association between the expression of these genes
and patient survival in an independent sample set. Some of these genes may
play important roles in gastric tumor progression. For example, a high level
of expression of IGF-2 was associated with poor patient survival (p < 0.002
by Cox regression assay). Overexpression of IGF-2 has been implicated in
progression and metastasis of many types of cancers, including colon cancer,
breast cancer, Wilm's tumor, and neuroblastoma
(Toretsky and Helman, 1996
).
The potential involvement of IGF-2 in the progression of gastric cancer
clearly warrants further investigation. Patients whose gastric cancers
expressed PLA2G2A, the gene encoding the group IIa secreted phospholipase A2,
at high levels, had a highly significant survival advantage (p < 0.002).
The murine ortholog of PLA2G2A, has been shown genetically to limit the
severity of intestinal neoplasia in the
Apcmin1/+ mouse, a mouse model of familial
adenomatous polyposis, suggesting that PLA2G2A may play a similar role in
suppressing progression of human gastric cancer
(MacPhee et al.,
1995
; Cormier et al.,
1997
). A more extensive analysis and discussion of the association
between PLA2G2A and gastric cancer progression is reported separately
(Leung et al.,
2002
).
In summary, a systematic study of gene expression patterns in human gastric cancers has revealed inherent molecular heterogeneity in gastric cancer, and identified multidimensional variations in gene expression patterns that distinguish gastric carcinoma and gastric mucosa in various preneoplastic stages. By using both supervised and unsupervised methods to search for relationships and systematic patterns in the data and by comparison of the expression patterns in the cancers with those seen in normal tissue of various histological types, we can begin to place features of this molecular variation into an interpretative framework that provides insights into the biological features and potential clues to the pathogenesis of these cancers. Differences among cancers in expression of specific genes may provide strong predictors of prognosis and suggest the potential utility of specific, molecularly targeted therapies.
| ACKNOWLEDGMENTS |
|---|
|
|
|---|
| Footnotes |
|---|
Supplementary Information is available through the author's Web supplement site at: http://genome-www.stanford.edu/Gastric_Cancer2.
Abbreviations used: EBV: Epstein-Barr virus; H. pylori: Helicobacter pylori.
These authors contributed equally to this work. ![]()

Corresponding author. E-mail address:
pbrown{at}cmgm.stanford.edu.
| REFERENCES |
|---|
|
|
|---|
Batlle, E., Henderson, J.T., Beghtel, H., van de Born, M.M.W., Sancho, E., Huls, G., Pawson, T., and Clevers, H. (2002). beta-catenin and TCF medicate cell positioning in the intestinal epithelium by controlling the expression of EphB/EphrinB. Cell 111, 251263.[CrossRef][Medline]
Cormier, R.T., Hong, K.H., Halberg, R.B., Hawkins, T.L., Richardson, P., Mulherkar, R., Dove, W.F., and Lander, E.S. (1997). Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat. Genet. 17, 8891.[CrossRef][Medline]
Correa, P. (1988). A human model of gastric
carcinogenesis. Cancer Res. 48,
35543560.
Dhanasekaran, S.M., Barrette, T.R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K.J., Rubin, M.A., and Chinnaiyan, A.M. (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822826.[CrossRef][Medline]
Dodelet, V.C., and Pasquale, E.B. (2000). Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 19, 56145619.[CrossRef][Medline]
El-Rifai, W., Frierson, H.F., Jr., Harper, J.C., Powell, S.M., and Knuutila, S. (2001). Expression profiling of gastric adenocarcinoma using cDNA array. Int. J. Cancer 92, 832838.[CrossRef][Medline]
Garber, M.E. et al. (2001). Diversity of gene
expression in adenocarcinoma of the lung. Proc. Natl. Acad. Sci.
USA 98,
1378413789.
Grabiec, J., and Owen, D.A. (1985). Carcinoma of the stomach in young persons. Cancer 56, 388396.[CrossRef][Medline]
Hedenfalk, I. et al. (2001). Gene-expression
profiles in hereditary breast cancer. N. Engl. J. Med.
344,
539548.
Hippo, Y., Taniguchi, H., Tsutsumi, S., Machida, N., Chong, J.M.,
Fukayama, M., Kodama, T., and Aburatani, H. (2002). Global gene
expression analysis of gastric cancer by oligonucleotide microarrays.
Cancer Res. 62,
233240.
Iyer, V.R. et al. (1999). The transcriptional
program in the response of human fibroblasts to serum. Science
283,
8387.
Korinek, V., Barker, N., Morin, P.J., van Wichen, D., de Weger, R.,
Kinzler, K.W., Vogelstein, B., and Clevers, H. (1997).
Constitutive transcriptional activation by a beta-catenin-Tcf complex in
APC-/- colon carcinoma. Science
275,
17841787.
Kullander, K., and Klein, R. (2002). Mechanisms and functions of Eph and ephrin signalling. Nat. Rev. Mol. Cell Biol. 3, 475486.[CrossRef][Medline]
Lauren, P. (1965). The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathology Microbiology Scand. 64, 3149.
Lefebvre, O., Chenard, M.P., Masson, R., Linares, J., Dierich, A.,
LeMeur, M., Wendling, C., Tomasetto, C., Chambon, P., and Rio, M.C.
(1996). Gastric mucosa abnormalities and tumorigenesis in mice
lacking the pS2 trefoil protein. Science
274,
259262.
Leung, S.Y., Chau, K.Y., Yuen, S.T., Chu, K.M., Branicki, F.J., and Chung, L.P. (1998). p53 overexpression is different in Epstein-Barr virus-associated and Epstein-Barr virus-negative carcinoma. Histopathology 33, 311317.[Medline]
Leung, S.Y. et al. (2002). Phospholipase A2
group IIA expression in gastric adenocarcinoma is associated with prolonged
survival and less frequent metastasis. Proc. Natl. Acad. Sci.
USA 99,
1620316209.
Lustig, B. et al. (2002). Negative feedback
loop of Wnt signaling through upregulation of conductin/axin2 in colorectal
and liver tumors. Mol. Cell. Biol.
22,
11841193.
MacPhee, M., Chepenik, K.P., Liddell, R.A., Nelson, K.K., Siracusa, L.D., and Buchberg, A.M. (1995). The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of Apc-Min-induced intestinal neoplasia. Cell 81, 957966.[CrossRef][Medline]
Nishi M, Omori. Y., Miwa, K., and editors, J. R. S. f. G. C. (1995). Japanese Classification of Gastric Carcinoma. Tokyo: Kanehara.
Parkin, D.M., Pisani, P., and Ferlay, J. (1999). Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80, 827841.[CrossRef][Medline]
Parsonnet, J., Friedman, G.D., Vandersteen, D.P., Chang, Y., Vogelman, J.H., Orentreich, N., and Sibley, R.K. (1991). Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325, 11271131.[Abstract]
Perou, C.M. et al. (2000). Molecular portraits of human breast tumours. Nature 406, 747752.[CrossRef][Medline]
Pomeroy, S.L. et al. (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436442.[CrossRef][Medline]
Riethmuller, G. et al. (1998). Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol. 16, 17881794.[Abstract]
Rosenwald, A. et al. (2001). Relation of gene
expression phenotype to immunoglobulin mutation genotype in B cell chronic
lymphocytic leukemia. J. Exp. Med.
194,
16391647.
Rosenwald, A. et al. (2002). The use of
molecular profiling to predict survival after chemotherapy for diffuse
large-B-cell lymphoma. N. Engl. J. Med.
346,
19371947.
Sherlock, G. et al. (2001). The Stanford
Microarray Database. Nucleic Acids Res.
29,
152155.
Shibata, D., and Weiss, L.M. (1992). Epstein-Barr virus-associated gastric adenocarcinoma. Am. J. Pathol. 140, 769774.[Abstract]
Shin, J.Y., Kim, H.S., Park, J., Park, J.B., and Lee, J.Y.
(2000). Mechanism for inactivation of the KIP family
cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer
Res. 60,
262265.
Sorlie, T. et al. (2001). Gene expression
patterns of breast carcinomas distinguish tumor subclasses with clinical
implications. Proc. Natl. Acad. Sci. USA
98,
1086910874.
Toretsky, J.A., and Helman, L.J. (1996). Involvement
of IGF-II in human cancer. J. Endocrinol.
149,
367372.
Troyanskaya, O., Cantor, M., Sherlock, G., Brown, P., Hastie, T.,
Tibshirani, R., Botstein, D., and Altman, R.B. (2001). Missing
value estimation methods for DNA microarrays. Bioinformatics
17,
520525.
Troyanskaya, O.G., Garber, M.E., Brown, P.O., Botstein, D., and
Altman, R.B. (2002). Nonparametric methods for identifying
differentially expressed genes in microarray data.
Bioinformatics 18,
14541461.
van't Veer, L.J. et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530536.[CrossRef][Medline]
Whitfield, M.L. et al. (2002). Identification
of genes periodically expressed in the human cell cycle and their expression
in tumors. Mol. Biol. Cell 13,
19772000.
Wu, M.S., Shun, C.T., Wu, C.C., Hsu, T.Y., Lin, M.T., Chang, M.C., Wang, H.P., and Lin, J.T. (2000). Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations. Gastroenterology 118, 10311038.[CrossRef][Medline]
Yuen, S.T., Chung, L.P., Leung, S.Y., Luk, I.S., Chan, S.Y., and Ho, J. (1994). In situ detection of Epstein-Barr virus in gastric and colorectal adenocarcinomas. Am. J. Surg. Pathol. 18, 11581163.[Medline]
This article has been cited by other articles:
![]() |
A. Sayi, E. Kohler, I. Hitzler, I. Arnold, R. Schwendener, H. Rehrauer, and A. Muller The CD4+ T Cell-Mediated IFN-{gamma} Response to Helicobacter Infection Is Essential for Clearance and Determines Gastric Cancer Risk J. Immunol., June 1, 2009; 182(11): 7085 - 7101. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Capoccia, W. J. Huh, and J. C. Mills How form follows functional genomics: gene expression profiling gastric epithelial cells with a particular discourse on the parietal cell Physiol Genomics, April 10, 2009; 37(2): 67 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kim, J.-H. Kim, H.-R. Jang, H.-M. Kim, C.-W. Lee, S.-M. Noh, K.-S. Song, J.-S. Cho, H.-Y. Jeong, Y. Hahn, et al. LRRC3B, Encoding a Leucine-Rich Repeat-Containing Protein, Is a Putative Tumor Suppressor Gene in Gastric Cancer Cancer Res., September 1, 2008; 68(17): 7147 - 7155. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. G. Leong, K. Niessen, I. Kulic, A. Raouf, C. Eaves, I. Pollet, and A. Karsan Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin J. Exp. Med., November 26, 2007; 204(12): 2935 - 2948. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yu, J. Yu, D. R. Rhodes, S. A. Tomlins, X. Cao, G. Chen, R. Mehra, X. Wang, D. Ghosh, R. B. Shah, et al. A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome Cancer Res., November 15, 2007; 67(22): 10657 - 10663. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nicolau, R. Tibshirani, A.-L. Borresen-Dale, and S. S. Jeffrey Disease-specific genomic analysis: identifying the signature of pathologic biology Bioinformatics, April 15, 2007; 23(8): 957 - 965. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Qiu, Z. J. Wang, K. J. R. Liu, Z.-Z. Hu, and C. H. Wu Dependence network modeling for biomarker identification Bioinformatics, January 15, 2007; 23(2): 198 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wang, Y. Lv, Z. Guo, X. Li, Y. Li, J. Zhu, D. Yang, J. Xu, C. Wang, S. Rao, et al. Effects of replacing the unreliable cDNA microarray measurements on the disease classification based on gene expression profiles and functional modules Bioinformatics, December 1, 2006; 22(23): 2883 - 2889. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Z. Ring, R. S. Seitz, R. Beck, W. J. Shasteen, S. M. Tarr, M. C.U. Cheang, B. J. Yoder, G. T. Budd, T. O. Nielsen, D. G. Hicks, et al. Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor-Positive Breast Cancer J. Clin. Oncol., July 1, 2006; 24(19): 3039 - 3047. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Guo, J. Zhang, S. T. Yuen, W. Y. Tsui, A. S.Y. Chan, C. Ho, J. Ji, S. Y. Leung, and X. Chen Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours Carcinogenesis, March 1, 2006; 27(3): 454 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Tsai, R. Herrera-Goepfert, R. J. Tibshirani, S. Yang, A. Mohar, J. Guarner, and J. Parsonnet Changes of Gene Expression in Gastric Preneoplasia following Helicobacter pylori Eradication Therapy. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 272 - 280. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Aggarwal, D. Li Guo, Y. Hoshida, S. Tsan Yuen, K.-M. Chu, S. So, A. Boussioutas, X. Chen, D. Bowtell, H. Aburatani, et al. Topological and Functional Discovery in a Gene Coexpression Meta-Network of Gastric Cancer Cancer Res., January 1, 2006; 66(1): 232 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, H. Zhao, Q. Xu, W. Jin, C. Liu, H. Zhang, Z. Huang, X. Zhang, Y. Zhang, D. Xin, et al. HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma Nucleic Acids Res., January 1, 2006; 34(suppl_1): D607 - D612. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Choi, U. Yu, O. J. Yoo, and S. Kim Differential coexpression analysis using microarray data and its application to human cancer Bioinformatics, December 15, 2005; 21(24): 4348 - 4355. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Giacomini, S. Y. Leung, X. Chen, S. T. Yuen, Y. H. Kim, E. Bair, and J. R. Pollack A Gene Expression Signature of Genetic Instability in Colon Cancer Cancer Res., October 15, 2005; 65(20): 9200 - 9205. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Hall, C. B. Todd, P. L. Hyland, S. S. McDade, H. Grabsch, M. Dattani, K. J. Hillan, and S.E. H. Russell The Septin-Binding Protein Anillin Is Overexpressed in Diverse Human Tumors Clin. Cancer Res., October 1, 2005; 11(19): 6780 - 6786. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mueller, S. Falkow, and M. R. Amieva Helicobacter pylori and Gastric Cancer: What can be Learned by Studying the Response of Gastric Epithelial Cells to the Infection? Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1859 - 1864. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Kim, H.-Y. Sohn, S. Y. Yoon, J.-H. Oh, J. O. Yang, J. H. Kim, K. S. Song, S.-M. Rho, H. S. Yoo, Y. S. Kim, et al. Identification of Gastric Cancer-Related Genes Using a cDNA Microarray Containing Novel Expressed Sequence Tags Expressed in Gastric Cancer Cells Clin. Cancer Res., January 15, 2005; 11(2): 473 - 482. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Yang, M. Y. Seo, H. J. Jeong, H.-C. Jeung, J. Shin, S. C. Kim, S. H. Noh, H. C. Chung, and S. Y. Rha Gene Copy Number Change Events at Chromosome 20 and Their Association with Recurrence in Gastric Cancer Patients Clin. Cancer Res., January 15, 2005; 11(2): 612 - 620. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhao, A. Langerod, Y. Ji, K. W. Nowels, J. M. Nesland, R. Tibshirani, I. K. Bukholm, R. Karesen, D. Botstein, A.-L. Borresen-Dale, et al. Different Gene Expression Patterns in Invasive Lobular and Ductal Carcinomas of the Breast Mol. Biol. Cell, June 1, 2004; 15(6): 2523 - 2536. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. BOTSTEIN Genomic Perspective and Cancer Cold Spring Harb Symp Quant Biol, January 1, 2003; 68(0): 417 - 424. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||